Waiting and seeing is not often the strategy employed when it comes to treating breast cancer, but a new clinical trial by the University of California, San Francisco, researchers are doing just that.

On Sept. 5, 2025, the U.S. Food and Drug Administration (FDA) approved Inlexzo (gemcitabine intravesical system) for adults ...

Forlong Biotechnology, a clinical-stage biotech company focusing on developing transformative cytokine therapies for patients ...

The phase 3 ALBAN trial tested atezolizumab plus BCG in BCG-naïve patients with high-risk, non-muscle-invasive bladder cancer (NMIBC).

Doctors may be able to spare patients unnecessarily aggressive breast cancer treatments by collecting and testing cancer ...

Learn the symptoms of bladder cancer —blood in the urine, pain, and irritation or obstruction when urinating —and when to see a healthcare provider.

Three abstracts to be presented at the 101st Annual Meeting of the Western Section of the American Urological Association, including baseline characteristics and demographics for patients enrolled in ...

AstraZeneca announced that its IMFINZI (durvalumab) regimen significantly reduced the risk of disease recurrence or death by 32 percent in patients with high-risk, non-muscle-invasive bladder cancer ...

Detailed price information for Artara Therapeutics Inc (TARA-Q) from The Globe and Mail including charting and trades.

The phase 3 POTOMAC trial tested durvalumab added to BCG in patients with high-risk non-muscle-invasive bladder cancer (NMIBC).

A genetic test helps identify women at higher risk of breast cancer after early-stage lesions, enabling more personalized ...